BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17085127)

  • 1. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
    Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ
    J Urol; 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PubMed ID: 17085127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
    Khoddami SM; Shariat SF; Lotan Y; Saboorian H; McConnell JD; Sagalowsky AI; Roehrborn CG; Koeneman KS
    BJU Int; 2004 Jul; 94(1):42-6. PubMed ID: 15217428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
    Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.
    Boorjian SA; Karnes RJ; Crispen PL; Rangel LJ; Bergstralh EJ; Sebo TJ; Blute ML
    J Urol; 2009 Jan; 181(1):95-104; discussion 104. PubMed ID: 19012937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
    Freedland SJ; Grubb KA; Yiu SK; Humphreys EB; Nielsen ME; Mangold LA; Isaacs WB; Partin AW
    J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
    Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Presti JC; Terris MK;
    J Urol; 2006 Apr; 175(4):1298-302; discussion 1302-3. PubMed ID: 16515984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
    J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing nature of high risk patients undergoing radical prostatectomy.
    Kane CJ; Presti JC; Amling CL; Aronson WJ; Terris MK; Freedland SJ;
    J Urol; 2007 Jan; 177(1):113-7. PubMed ID: 17162017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
    Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
    Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.